*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
NewRiver was forced to confirm that it has entered a period of exclusivity with Hawthorn Leisure Holdings and its major shareholder regarding a potential acquisition of the business on Monday.
AstraZeneca received US regulatory approval for its Lokelma treatment for high potassium levels in the blood and, separately, submitted a new drug application in Japan for a diabetes treatment.
FTSE 250 gambling software group Playtech said on Monday that its acquisition of 71% of Italian gaming company Snaitech has been approved by the Italian gaming regulator.
